Results 251 to 260 of about 226,969 (309)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2002
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
IDrugs : the investigational drugs journal, 2003
AstraZeneca (formerly Astra) is developing tesaglitazar, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of diabetes and insulin resistance [275466], [377656]. Early phase clinical trials for both of these indications were ongoing in July 2002 [459440].
openaire +1 more source
AstraZeneca (formerly Astra) is developing tesaglitazar, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of diabetes and insulin resistance [275466], [377656]. Early phase clinical trials for both of these indications were ongoing in July 2002 [459440].
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a ...
openaire +1 more source
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a ...
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2002
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the potential prevention and treatment of venous thromboembolism (VTE) in hip and knee replacement, for prevention of stroke in atrialfibrillation (AF) and for post acute coronary syndrome.
openaire +1 more source
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the potential prevention and treatment of venous thromboembolism (VTE) in hip and knee replacement, for prevention of stroke in atrialfibrillation (AF) and for post acute coronary syndrome.
openaire +1 more source
IDrugs : the investigational drugs journal, 2005
AR-C68397AA is a dual dopamine D(2)-receptor and beta(2)-adrenoceptor agonist and bronchodilator under development by AstraZeneca (formerly Astra) and undergoing phase I trials for asthma and phase II trials for chronic obstructive pulmonary disease (COPD). AstraZeneca expects to file for drug registration in 2004.
openaire +1 more source
AR-C68397AA is a dual dopamine D(2)-receptor and beta(2)-adrenoceptor agonist and bronchodilator under development by AstraZeneca (formerly Astra) and undergoing phase I trials for asthma and phase II trials for chronic obstructive pulmonary disease (COPD). AstraZeneca expects to file for drug registration in 2004.
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2003
AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of December 2001, AZD-2563 had completed an escalating-dose phase I trial in the UK and was being developed in the US ...
openaire +1 more source
AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of December 2001, AZD-2563 had completed an escalating-dose phase I trial in the UK and was being developed in the US ...
openaire +1 more source
ASTRAZENECA INKS BIOLOGICS PACT
Chemical & Engineering News Archive, 2004ASTRAZENECA AND CAMbridge Antibody Technology (CAT) have formed a five-year R&D agreement under which they will pursue monoclonal antibody research, in the area of inflammatory disorders. AstraZeneca will pay $ 140 million for a 20% equity stake in the U.K.-based biopharmaceutical company The two plan to invest at least $175 million in the project ...
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
AstraZeneca (formerly Zeneca) is developing ZD-9331, a non-polyglutamatable thymidylate synthase inhibitor, as a potential treatment for solid tumors and other neoplasia, including colorectal tumors [216476,179954,179955]. ZD-9331 is being developed as both an oral and an i.v.
openaire +1 more source
AstraZeneca (formerly Zeneca) is developing ZD-9331, a non-polyglutamatable thymidylate synthase inhibitor, as a potential treatment for solid tumors and other neoplasia, including colorectal tumors [216476,179954,179955]. ZD-9331 is being developed as both an oral and an i.v.
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
AstraZeneca is developing ZD-1839, an inhibitor of epidermal growth factor receptor 1 (EGFR1) tyrosine kinase, for potential treatment of cancers which overexpress EGF receptors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [196279], [270898].
openaire +1 more source
AstraZeneca is developing ZD-1839, an inhibitor of epidermal growth factor receptor 1 (EGFR1) tyrosine kinase, for potential treatment of cancers which overexpress EGF receptors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [196279], [270898].
openaire +1 more source
Chemical & Engineering News Archive, 2013
In a bid to stay competitive in treating respiratory diseases, AstraZeneca is paying up to $1.15 billion for the privately held biotech firm Pearl Therapeutics. The acquisition is the latest in the British drug company’s piecemeal rebuilding of a new-product pipeline that has fallen apart in recent years.
openaire +1 more source
In a bid to stay competitive in treating respiratory diseases, AstraZeneca is paying up to $1.15 billion for the privately held biotech firm Pearl Therapeutics. The acquisition is the latest in the British drug company’s piecemeal rebuilding of a new-product pipeline that has fallen apart in recent years.
openaire +1 more source